Frecuencia de eventos cardiovasculares en pacientes con lupus eritematoso sistémico / Frequency of cardiovascular events in patients with systemic lupus erythematosus

Resumen Introducción: el progreso en los tratamientos para el lupus eritematoso sistémico (LES) resultó en una disminución de la mortalidad; sin embargo, la enfermedad cardiovascular y las complicaciones infecciosas aún son las principales causas de muerte. La evidencia apoya la participación del sistema inmunológico en la generación de la placa aterosclerótica, así como su conexión con las enfermedades autoinmunes. Objetivos: describir la frecuencia de eventos cardiovasculares (ECV) en el Registro de Lupus Eritematoso Sistémico de la Sociedad Argentina de Reumatología (RELESSAR) transversal, así como sus principales factores de riesgo asociados. Materiales y métodos: estudio descriptivo y transversal para el cual se tomaron los pacientes ingresados en el registro RELESSAR transversal. Se describieron las variables sociodemográficas y clínicas, las comorbilidades, score de actividad y daño. ECV se definió como la presencia de al menos una de las siguientes patologías: enfermedad arterial periférica, cardiopatía isquémica o accidente cerebrovascular. El evento clasificado para el análisis fue aquel posterior al diagnóstico del LES. Se conformaron dos grupos macheados por edad y sexo 1:2. Resultados: 1515 pacientes mayores de 18 años participaron del registro. Se describieron 80 pacientes con ECV (5,3%). En este análisis se incluyeron 240 pacientes conformando dos grupos. La edad media fue de 47,8 (14,4) y 47,6 (14,2) en el grupo con y sin ECV respectivamente. Los pacientes con ECV tuvieron mayor duración del LES en meses, mayor índice de Charlson, mayor SLICC (Systemic Lupus International Collaborating Clinics/American College of Rheumatology), mayor frecuencia de manifestaciones neurológicas, síndrome antifosfolípido, hospitalizaciones y uso de ciclofosfamida. Las únicas variables asociadas en el análisis multivariado fueron el índice de Charlson (p=0,004) y el SLICC (p<0,001). Conclusiones: los ECV influyen significativamente en nuestros pacientes, y se asocian a mayor posibilidad de daño irreversible y comorbilidades.

Abstract Introduction: progress in treatments for systemic lupus erythematosus (SLE) has resulted in a decrease in mortality; however, cardiovascular and infectious diseases remain the leading causes of death. Evidence supports the involvement of the immune system in the generation of atherosclerotic plaque, as well as its connection to autoimmune diseases. Objectives: to describe the frequency of cardiovascular disease (CVD) in the cross-sectional RELESSAR registry, as well as its associated variables. Materials and methods: a descriptive and cross-sectional study was performed using patients admitted to the cross-sectional RELESSAR registry. Sociodemographic variables, clinical variables, comorbidities, activity and damage scores were described. CVD was defined as at least one of the following: peripheral arterial disease, ischemic heart disease, or cerebrovascular accident. All patients with at least one CVD were included in our analysis (heart attack, central nervous system vascular disease, and peripheral arteries atherosclerotic disease). The event classified for the analysis was that after the diagnosis of SLE. SLE diagnosis was previous to CVD. Two groups matched by age and sex, 1:2 were formed. Results: a total of 1515 patients older than 18 years participated in the registry. Eighty patients with CVD (5.3%) were described in the registry. Two-hundred and forty patients were included, according to two groups. The mean age was 47.8 (SD 14.4) and 47.6 (SD 14.2) in patients with and without CVD, respectively. Patients with CVD had a longer duration of SLE in months, a higher Charlson index, a higher SLICC, increased frequency of neurological manifestations, antiphospholipid syndrome, hospitalizations, and use of cyclophosphamide. The associated variables in the multivariate were the Charlson Index (p=0.004) and the SLICC (p<0.001). Conclusions: CVDs have a significant influence on our patients, being associated with a greater possibility of damage and comorbidities.

Endoprótesis coronaria y doble terapia antiplaquetaria prolongada. Un estudio longitudinal / Coronary stent and prolonged dual antiplatelet therapy. A longitudinal study

Resumen Introducción: En las guías actuales europeas para el manejo del infarto de miocardio posterior a la colocación de endoprótesis coronaria (stent), no existe consenso sobre la duración ideal de la terapia antiagregante plaquetaria dual (DAPT, dual antiplatelet therapy) para prevenir la trombosis-reestenosis del stent sin aumentar el riesgo significativo de sangrado. Objetivo: Reportar el porcentaje de sangrado mayor y de eventos cardiovasculares mayores asociados a la DAPT prolongada en pacientes atendidos en el Instituto Nacional de Cardiología y tratados con intervención coronaria percutánea primaria y stent. Métodos: Se realizó un estudio longitudinal, prospectivo observacional y descriptivo no experimental. Los pacientes fueron captados de noviembre de 2016 a diciembre de 2017. Resultados: Fueron seleccionados 135 pacientes con una media de edad de 57 ± 10 años, quienes cumplieron un seguimiento clínico por tres años. La obesidad y la hipertensión destacaron como principales factores de riesgo. Posterior al uso de DAPT durante tres años, se registró 3.7 % de mortalidad, 1.48 % de sangrado mayor y 4.4 % de trombosis-reestenosis. Conclusiones: El uso prolongado de DAPT estaría justificado por la alta incidencia de trombosis-reestenosis, sin incremento significativo en el riesgo de sangrado y con disminución de los eventos cardiovasculares mayores.

Abstract Introduction: In current European guidelines for the management of myocardial infarction after coronary stent placement, there is no consensus on dual antiplatelet therapy (DAPT) ideal duration to prevent stent thrombosis-restenosis without significantly increasing the bleeding risk. Objective: To report the percentage of major bleeding and presence of major cardiovascular events associated with prolonged DAPT in patients recruited at the National Institute of Cardiology, treated with primary percutaneous coronary intervention and stent. Methods: A longitudinal, prospective, observational, non-experimental, descriptive study was carried out. Patients were recruited from November 2016 to December 2017. Results: One-hundred and thirty-five patients with a mean age of 57 ± 10 years who completed the three-year follow-up were selected. Obesity and hypertension stood out as the main risk factors. After using DAPT for three years, 3.7% of mortality, 1.48% of major bleeding, and 4.4% of thrombosis-restenosis were recorded. Conclusions: Prolonged use of DAPT would be justified by the high incidence of thrombosis-restenosis, without a significant increase in bleeding risk, as well as a decrease in major cardiovascular events.

Mesa 3: Efectos cardiovasculares de fármacos antidiabéticos / Table 3: Cardiovascular effects of anti-diabetic drugs

Los eventos cardiovasculares representan la mayor complicación de la diabetes. La evidencia sugiere que la metformina mejora los resultados cardiovasculares en pacientes con diabetes, especialmente en el United Kingdom Prospective Diabetes Study (UKPDS) y otros estudios posteriores, por distintos mecanismos. Hay pocos estudios de seguridad cardiovascular para sulfonilureas aunque no tendrían un perfil seguro a este nivel. La gliclazida parece ser la de mejor performance de las drogas de este grupo. Algo similar ocurre con las meglitinidas, para las cuales los datos indican que no aumentarían el riesgo pero tampoco mejorarían la incidencia de eventos cardiovasculares. Las tiazolidinedionas son las drogas más cuestionadas, aunque los estudios y metaanálisis son contradictorios no habría dudas que aumentan el riesgo de insuficiencia cardíaca. Los inhibidores de la DPPIV mostraron resultados neutros a excepción de saxagliptina que aumentaría el riesgo de internación por insuficiencia cardíaca. Existen datos convincentes que los inhibidores de los receptores SGLT-2 a nivel renal y los análogos del GLP-1 intestinal tienen efectos positivos a nivel cardiovascular, con algunas diferencias entre los integrantes de esta familia. En cuanto a las insulinas, los estudios sugieren que tanto los análogos lentos como rápidos tendrían un mejor perfil cardiovascular, ligado principalmente a la menor incidencia de hipoglucemias severas, que insulina NPH y regular respectivamente.

Cardiovascular events represent the greatest complication of diabetes. Evidence suggests that metformin improves CV outcomes in patients with diabetes, especially in the United Kingdom Prospective Diabetes Study (UKPDS) and other subsequent studies, by different mechanisms. There are few cardiovascular safety studies for sulfonylureas although they would not have a safe profile at this level. Gliclazide appears to be the best performing drug in this group. Something similar occurs with meglitinides for which the data indicates that they would not increase the risk but neither would they improve the incidence of cardiovascular events. Thiazolidinediones are the most questioned drugs, although the studies and meta-analyzes are contradictory, there would be no doubt that they increase the risk of heart failure. DPPIV inhibitors showed neutral results except for saxagliptin, which would increase the risk of hospitalization for heart failure. There is convincing data that SGLT-2 receptor inhibitors at the renal level and intestinal GLP-1 analogues have positive effects at the cardiovascular level with some differences between the members of these families. Regarding insulins, studies suggest that both slow and fast analogues would have a better cardiovascular profile, mainly linked to the lower incidence of severe hypoglycemia, than NPH and regular insulin, respectively

Eventos cardiovasculares y su relación con cambios tensionales / Cardiovascular events and their relation to tension changes

RESUMEN La tensión arterial no es constante, y cambia frecuentemente en respuesta a estímulos fisiológicos de la vida diaria. Se realizó una revisión sistemática en inglés y español de los principales artículos publicados en PubMed, Scielo y MEDLINE durante el periodo comprendido desde el año 2010 hasta 2018, acerca de la variabilidad de la tensión arterial y sus complicaciones. Esto se ha documentado por el uso de la medición ambulatoria de la tensión arterial, una técnica que cada vez está más disponible para medir la tensión arterial y sus variaciones durante el día y la noche, con una frecuencia regular cada 15- 30 minutos a lo largo de un periodo de 24 horas. Esta técnica ha demostrado la diferencia de la tensión arterial en las diferentes mediciones durante el día y la noche, estos cambios en tan corto tiempo son predictores de las complicaciones cardiovasculares independiente de los valores absolutos (AU).

SUMMARY Blood pressure is not constant, and changes frequently in response to the physiological stimuli of everyday living. Was carried out a systematic revision in English and Spanish of the main articles published in PubMed, Scielo and MEDLINE during the period from the year 2010 up to 2018, about the variability of the Blood pressure and his complication. This has been documented by the use of ambulatory Blood pressure monitoring, a technique becoming more widely available that measures Blood pressure at regular intervals-typically each 15-30 min-throughout a 24-h period. This technique has demonstrated that differences among the daylong multiple readings-labelled as short-term variability-are predictive of cardiovascular outcomes independent of absolute Blood pressure levels (AU).

Efectos cardiovasculares de los nuevos fármacos no insulínicos en diabetes / Cardiovascular effects of new non-insulinic anti-diabetes drugs]

La diabetes mellitus constituye actualmente un grave problema de salud pública a nivel mundial, que incrementa el riesgo de presentar complicaciones tanto microvasculares como macrovasculares. Aunque lograr los objetivos de glucemia recomendados reduce el riesgo de complicaciones microvasculares, el efecto de los fármacos para tratar la hiperglucemia sobre las complicaciones macrovasculares y la muerte cardiovascular es motivo de preocupación. En este contexto, las agencias regulatorias han modificado la normativa para la aprobación de nuevos fármacos en diabetes, de forma que establecen la necesidad de demostrar que son capaces de disminuir la glucemia junto con una evaluación sólida de la seguridad cardiovascular. El objetivo de este trabajo es revisar los efectos cardiovasculares de las nuevas familias de fármacos no insulínicos, en especial en su efecto sobre el riesgo de eventos cardiovasculares mayores. En los últimos años, finalmente, se ha confirmado que algunos fármacos para tratar la diabetes no solo son seguros desde el punto de vista cardiovascular, sino que incluso han mostrado capacidad para reducir el riesgo de enfermedad cardiovascular en la diabetes mellitus tipo 2. La evidencia obtenida ha determinado la actualización de algunas guías terapéuticas vigentes cuando el riesgo cardiovascular debería considerarse una variable fundamental al momento de la elección terapéutica en pacientes con diabetes.

Diabetes mellitus is currently a serious public health problem worldwide, that increases the risk of presenting microvascular and macrovascular complications. Although achieving the recommended blood glucose goals reduces the risk of microvascular complications, the effect of the drugs used to treat hyperglycemia on macrovascular complications and cardiovascular death is a cause for concern. In this context, the regulatory agencies have modified the regulations for the approval of new drugs in diabetes, by adding the need to demonstrate that they are capable of lowering blood glucose levels together with a solid assessment of cardiovascular safety. The objective of this study is to review the cardiovascular effects of the new families of non-insulin drugs, with special emphasis on their effect on the risk of major cardiovascular events. In recent years, it has finally been confirmed that some of the drugs used to treat diabetes are not only safe from a cardiovascular point of view, but have even shown capacity to reduce the risk of cardiovascular disease in type 2 diabetes mellitus. The evidence obtained determined the updating of some current therapeutic guidelines when cardiovascular risk should be considered a fundamental variable at the time of therapeutic choice in patients with diabetes.

Clinical and Functional Outcome of Percutaneous alcohol septal ablation in Obstructive Hypertrophic Cardiomyopathy / Resultados clínicos y funcionales de la ablación septal percutánea con alcohol en la miocardiopatía hipertrófica obstructiva

background: Percutaneous septal ablation is a therapeutic option for patients with obstructive hypertrophic cardiomyopathy refrac-tory to optimal medical therapy. However, results of initial persistence and long-term safety are still controversial. Objectives: The aim of this study was to report percutaneous alcohol septal ablation technique, clinical and functional outcome, cardiovascular events and its impact on long-term follow-up. Methods: A total of 23 patients were included in the study. Functional class (FC), left ventricular outflow tract gradient before and after the procedure and long-term cardiovascular events were evaluated. results: Median follow-up was 52 months (IR 33-72). All patients were in FC III or IV prior to the procedure, under maximum tolerated medical therapy. The procedure was successful in 91% of cases, with 85% of patients currently in FC I and 15% in FC II. Baseline left ventricular outflow tract gradient decreased from 75 mmHg (95% CI 51-89) to 25 mmHg (95% CI 10-37) (p <0.003) and with Valsalva maneuver from 118 mmHg (95% CI 88-152) to 38 mmHg (95% CI 16-69) (p <0.0002), persisting in the long-term follow-up. During hospitalization, two patients presented with complete atrioventricular block requiring permanent pacemaker implantation. No cardiovascular deaths occurred during follow up. Conclusions: Alcohol septal ablation is a promising option for the treatment of a selected population with hypertrophic obstructive cardiomyopathy, generating sustained clinical and functional improvement with low incidence of events in the long-term follow up.

Factores de riesgo cardiovascular en síndrome metabólico / Cardiovascular risk factors in metabolic syndrome

El síndrome metabólico es un grupo de factores de riesgo para desarrollar evento coronario; alteración del metabolismo de la glucosa, diabetes, obesidad abdominal, dislipidemia e hipertensión forman parte de él. Seestima que una cuarta parte de la población adulta lo presenta, tienen dos veces de riesgo de morir y tresveces más riesgo de padecer algún evento coronario o evento Cerebrovascular comparado a quienes no lopresentan. También las personas tienen cinco veces más posibilidad de desarrollar diabetes tipo 2. Laspatologías que lo conforman, parecen tener una interrelación fisiopatológica, que las va uniendo. Laspoblaciones latinoamericanas presentan características que las hacen especialmente susceptibles a padecerestas patologías cardio-metabólicas. El reconocimiento de estas características en los pacientes tiene unaimportancia especial debido a que indica la necesidad de aplicar medidas activas para reducir el riesgo cardiovascular.

Metabolic syndrome is a group of the most dangerous risk factors for coronary event, alteration in glucosemetabolism; diabetes, abdominal obesity, dyslipidemia and hypertension are components of this. It isestimated that a quarter of the adult population has it, they have twice probabilities to die, three times as likelyto coronary event or Cerebrovascular event compared to those do not have it. Also people are five times morelikely at risk for type 2 Diabetes. The pathologies that comprise it seem to have a pathophysiologicalinterrelationship, which puts together. Latin American populations have characteristics that make themespecially susceptible to these cardiometabolic diseases. Recognition of these characteristics in patients isparticularly important because it indicates the need for active measures to reduce cardiovascular risk.

Grosor de la íntima-media carotídea como predictor de evento cardiovascular: revisión sistemática de la literatura / Thickness of carotid intima-media as a predictor of cardiovascular event: systematic review of the literature

La ateroesclerosis es una enfermedad y evolutiva crónica que afecta a todas las arterias del organismo. Existen numerosos factores de riesgo (FR) relacionados, sin embargo un tercio de los eventos cardiovasculares (ECV) no son atribuibles a los FR conocidos. Existe evidencia que la medición del grosor de íntima-media (GIM) permite evaluar estados precoces de la enfermedad y la carótida es una localización adecuada para ello. El objetivo de este estudio es determinar si la evidencia disponible avala al GIM carotídea (GIMC), como factor asociado al desarrollo de ECV o muerte, en adultos asintomáticos de la población general. Revisión sistemática de la literatura. Se analizaron estudios primarios publicados de 2006 a la fecha, sin restricción de diseño ni de idioma; que incluyeran población adulta, sin antecedentes de ECV; y en los que se considerara la medición del GIMC mediante ultrasonografía. Se consultó las bases de datos MEDLINE, SciELO y LILACS. Se utilizaron términos MeSH y palabras libres. La calidad metodológica (CM) de los estudios seleccionados fue determinada mediante un escore validado para tal efecto. Se valoraron las siguientes variables: edad, género, raza; antecedentes de diabetes mellitus (DM), hipertensión arterial (HTA), dislipidemia, tabaquismo, obesidad y CM de los estudios primarios. Las estrategias de búsqueda permitieron recuperar 9 estudios primarios, que incluyen 24016 pacientes; 54,3% de los cuales son de género femenino. El FR asociado más frecuentemente fue el hábito de fumar (54%), seguido por HTA y DM. Las mediciones ultrasonográficas permitieron verificar una amplia variedad de técnicas utilizadas tanto en carótida común como en carótida interna y externa. Se verificó gran heterogeneidad en las técnicas de medición, lo que impide comparar en sentido estricto los resultados obtenidos; por ende, la evidencia disponible no permite determinar asociación entre GIMC y ECV en adultos asintomáticos de la población general. Se requieren estudios de mejor nivel de evidencia y CM para aclarar esta incertidumbre.

Atherosclerosis is a chronic and evolutionary disease that affects all the arteries of the body. There are many risk factors (RF) related, but a third of cardiovascular events (CVE) are not attributable to traditional RF. There is evidence that the measurement of intima-media diameter allows evaluation at early stages of the disease and carotid artery is a suitable location for it (CIMD). The aim of this study is to determine whether the available evidence supports the CIMD as a factor associated with the development of CVE or death in asymptomatic adults in the general population. Systematic review. We analyzed studies primary studies published from 2006 to date, without restriction of language or design, to include adult population with no history of CVE and in those that CIMD was measurement by ultrasound. MEDLINE, SciELO and LILACS databases were consulted. MeSH terms and free words were used. Selected studies were analyzed using MINCIR methodological quality (MQ) scores of therapy and prognosis. The following variables were considered: age, gender, race, history of diabetes, hypertension, dyslipidemia, smoking, obesity and MQ of primary studies. Results: 9 primary studies were analyzed, including 24,016 patients, 54.3% of whom are female. The RF more frequently reported and associated with CVE were smoking (54%) followed by hypertension and diabetes. Ultrasonographic measurements allowed us to verify a wide variety of techniques used, indicating a large heterogeneity and therefore not possible to compare the results. The available evidence to determine the association between CIMD and CVE is insufficient. Studies with better level evidence and MQ are needed to clarify the uncertain.

Análise de eficácia, eventos adversos e desfechos cardiovasculares em estudos relacionados às combinações de nifedipino GITS ou anlodipino com medicamentos que atuam no sistema renina angiotensina aldosterona / Efficacy analysis, adverse events and cardiovascular outcomes in studies related to combinations of nifedipine GITS or amlodipine with drugs acting on the renin angiotensin aldosterone system

Revisamos 17 estudos com o objetivo de avaliar a eficácia anti-hipertensiva da combinação de antagonistas de cálcio com bloqueadores dos receptores de angiotensina na redução da pressão arterial, de desfechos cardiovasculares e na incidência de efeitos adversos. A terapia combinada de bloqueador de canais de cálcio anlodipino ou nifedipino GITS, mais o bloqueador de receptor de angiotensina II valsartana, mostrou-se, na maioria dos estudos, mais eficaz que a monoterapia para redução de pressão arterial, além de mais benéfica quanto à diminuição de eventos cardiovasculares. O perfil de segurança e tolerabilidade das combinações também se revelou bastante aceitável, com o manejo de efeitos adversos favorecido pela maior possibilidade de ajustes de doses de substâncias com diferentes mecanismos de ação, sem comprometimento da eficácia anti-hipertensiva.

We reviewed 17 studies in order to evaluate the antihypertensive efficacy on the combination of calcium antagonists and angiotensin receptor blockers in lowering the blood pressure, cardiovascular outcomes and incidence of side effects. The combination therapy of amlodipine or nifedipine GITS calcium channel blockers, and angiotensin II receptor blocker valsartan showed, in most studies, more effective than monotherapy to lower blood pressure, as well as more beneficial to decrease cardiovascular events. The safety profile and tolerability of the combinations also proved quite acceptable, with side effects management benefited by higher possibility of adjustments on doses of substances with different mechanisms of actions, without affecting the antihypertensive efficacy.

La depresión como factor de riesgo cardiovascular en la vejez / Depression as a Cardiovascular Risk Factor in Old Age

Se realiza una revisión de trabajos sobre la comorbilidad entre la depresión y el factor de riesgo cardiovascular en la vejez. Se considera la importancia del diagnóstico de depresión en la vejez que suele subdiagnosticarse con los riesgos pertinentes, entre ellos la elevada morbimortalidad cardiovascular, con el objetivo de realizar un tratamiento adecuado de ambas patologías. Se evalúan los factores de riesgo, genéticos, personalidad, la sintomatología semejante de la depresión geriátrica con enfermedades médicas, la comorbilidad, sus mecanismos fisiopatológicos, neuroendócrinos, activación plaquetaria, hipercoagulabilidad, inflamatorios, citoquinas, disfunción endotelial.Se presentan estudios controlados psicofarmacológicos para poder realizar una adecuada elección del antidepresivo teniendo en cuenta la polifarmacia frecuente en este grupo etario y las posibles interacciones. Así mismo, la declaración de la Asociación Psiquiátrica Europea (EPA), con el apoyo de la Asociación Europea para el Estudio de la Diabetes (EASD) y la Sociedad Europea de Cardiología (ESC) para el cuidado interdisciplinario del enfermo psiquiátrico.

A review of studies on the comorbility between depression and cardiovascular risk factor in old age. We consider the magnitude of diagnosis of depression in old age often sub-diagnosed with the relevant risks, including the high cardiovascular morbidity and mortality in order to make appropriate treatment of both pathologies. We evaluated risk factores, genetic, personality, similar symptoms of geriatric depression with medical illness, comorbidity, pathophysiologic mechanisms, neuroendocrine, platelet activation, hypercoagulability, inflamatory cytokines, and endothelial dysfunction. Psychopharmacological controlled studies are presented to perform an adquate antidepressant choice considering the frequent polypharmacy and possible interactions in this age group. Likewise the statement of the European Psychaitric Association (EPA), with support from The European Assocation for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) for interdisciplinary care of psychiatric patient.

Dor torácica na emergência de um hospital geral / Thoracic pain in a general hospital emergency

Introdução: Dentre as doenças cardiovasculares, a condição mais prevalente é a dor torácica aguda não traumática. Objetivo: Identificar a freqüência de dor torácica na emergência e a descrição dos eventos na internação em 6 meses. Métodos: O estudo apresenta duas etapas: estudo transversal e série de casos, em pacientes com dor torácica na emergência, onde foi avaliado o protocolo assistencial. A dor foi classificada nas categorias: infarto agudo do miocárdio (IAM), angina pectoris e dor não-anginosa, de acordo com a clínica, eletrocardiografia e marcadores de necrose miocárdica. O teste ergométrico foi realizado de acordo com protocolo de Bruce. Os eventos em 6 meses foram mensurados. Resultados: No período de novembro de 2004 a janeiro de 2005 foram atendidos 80.184 pacientes na emergência do Hospital Conceição (HNSC). Desses atendimentos, 1.564 (2%) apresentavam dor torácica. Foram avaliados 52 pacientes, 34 (65%) masculino, idade média de 59 anos (dp 14,74), 69% internaram (38% com infarto, 27% angina e 4% dor não-anginosa), 17% realizaram teste ergométrico. Conclusão: Constatou-se uma baixa freqüência (2%) dos atendimentos devido a dor torácica não-traumática, porém elevada incidência de infarto e angina instável (AU)

Introduction: Among the cardiovascular emergencies the most frequent cause is nontraumatic acute thoracic pain in the emergency room. Objective: To identify thoracic pain frequency in the emergency and cardiovascular events in 6 months. Methods: A crosssectional and a case series study were carried out to evaluate thoracic pain guideline. Myocardial infarct, angina pectoris, and non-angina pain were identified based on clinical features, ECG abnormality and myocardial necrosis indicators. The ergometric test was carried out according to the Bruce Protocol. The events in 6 months were measured. Results: Between November 2004 through January 2005, 80,184 patients received care in the emergency room of Hospital Conceição. Among them, 1564 (2%) had thoracic pain. We had investigated 52 of these patients, 34 (65%) of whom were males, with an average age of 59 years old (sd 14.74). Regarding to the diagnosis, 69% had been admitted (38% with the diagnosis of infarct, 27% with angina and 4% with non-angina pain), 17% performed the ergometric test. Conclusion: A low frequency (2%) of non-traumatic thoracic pain has been identified, although there was a high incidence of infarct and unstable angina in these patients. There was a high prevalence of cardiovascular events in 6 months in the three studied groups (AU)

Control de la hipertensión arterial con medicamentos: actualización 2005 / Pharmacologic control of high blood pressure: up to date 2005

El uso adecuado de los medicamentos antihipertensivos es fundamental para garantizar el cumplimiento de las metas de presión arterial y la adherencia de los pacientes al tratamiento de la hipertensión, elementos necesarios para cumplir con el objetivo fundamental de disminuir el riesgo absoluto cardiovascular de los pacientes. Esta es una revisión narrativa basada en una búsqueda sistemática de la literatura, en la cual se seleccionaron los estudios aleatorizados controlados de terapia antihipertensiva inicial y se compararon tratamientos entre fármacos de dos o más grupos, que tengan como desenlace la reducción de eventos cardiovasculares.

Adequate use of antihypertensive drugs is one of the key elements to guarantee the achievement of blood pressure goals and the adherence of patients to treatment, in order to diminish the absolute cardiovascular risk. This article is a narrative review based on a systematic literature search in which randomized, controlled studies of initial antihypertensive therapy were selected and treatments with drugs of two or more groups were compared having as outcome the reduction of cardiovascular events.